Literature DB >> 18192107

Successful combined use of tranexamic acid and unfractionated heparin for life-threatening bleeding associated with intravascular coagulation in a patient with chronic myelogenous leukemia in blast crisis.

Mihoko Koseki1, Noboru Asada, Hidetaka Uryu, Masami Takeuchi, Hidesaku Asakura, Kosei Matsue.   

Abstract

The current therapeutic strategy for disseminated intravascular coagulation (DIC) is limited to control of the underlying disease, and methods for the effective management of DIC have not been established. We report the successful use of tranexamic acid (TA) combined with unfractionated heparin in a patient with life-threatening bleeding from the sigmoid colon caused by DIC. A 35-year-old man who had undergone allogeneic bone marrow transplantation for chronic myelogenous leukemia was referred for relapse of his leukemia. The patient was first treated with imatinib at 600 mg/day. Although the disappearance of leukemic cells and a decrease in the BCR/ABL fusion gene were observed, he developed massive bleeding from the sigmoid colon after defecation. A laboratory diagnosis of DIC with prominent fibrinolysis was based on elevated levels of both plasmin-alpha2-plasmin inhibitor complex and thrombin-antithrombin III complex. Despite vigorous supportive therapy, including multiple transfusions and aggressive fluid resuscitation, the patient developed hypovolemic shock due to the uncontrollable bleeding. TA combined with unfractionated heparin was instituted to inhibit excessive fibrinolysis. A prompt response was observed soon after the commencement of therapy. No organ dysfunction was observed throughout TA and heparin use. To our knowledge, this report is the first to describe successful treatment with TA combined with heparin for life-threatening intestinal bleeding due to acute DIC associated with hematologic malignancy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18192107     DOI: 10.1007/bf02983996

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  19 in total

Review 1.  Disseminated intravascular coagulation.

Authors:  M Levi; H Ten Cate
Journal:  N Engl J Med       Date:  1999-08-19       Impact factor: 91.245

Review 2.  Current understanding of disseminated intravascular coagulation.

Authors:  Marcel Levi
Journal:  Br J Haematol       Date:  2004-03       Impact factor: 6.998

Review 3.  Reassessing the hemostatic disorder associated with acute promyelocytic leukemia.

Authors:  M S Tallman; H C Kwaan
Journal:  Blood       Date:  1992-02-01       Impact factor: 22.113

4.  Annexin II and bleeding in acute promyelocytic leukemia.

Authors:  J S Menell; G M Cesarman; A T Jacovina; M A McLaughlin; E A Lev; K A Hajjar
Journal:  N Engl J Med       Date:  1999-04-01       Impact factor: 91.245

5.  Prevention of severe bleeding by tranexamic acid in a patient with disseminated intravascular coagulation.

Authors:  A Takada; Y Takada; T Mori; S Sakaguchi
Journal:  Thromb Res       Date:  1990-04-15       Impact factor: 3.944

6.  Myeloid leukaemic cells can lyse fibrin directly.

Authors:  L Robbie; S Berry; E Moir; N A Booth; D Culligan; J Tighe; H Watson; D King; B Bennett
Journal:  Br J Haematol       Date:  2000-11       Impact factor: 6.998

7.  Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients.

Authors:  F Rodeghiero; G Avvisati; G Castaman; T Barbui; F Mandelli
Journal:  Blood       Date:  1990-06-01       Impact factor: 22.113

8.  Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia.

Authors:  G Avvisati; J W ten Cate; H R Büller; F Mandelli
Journal:  Lancet       Date:  1989-07-15       Impact factor: 79.321

9.  Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage.

Authors:  S Hashimoto; T Koike; W Tatewaki; Y Seki; N Sato; T Azegami; N Tsukada; H Takahashi; H Kimura; M Ueno
Journal:  Leukemia       Date:  1994-07       Impact factor: 11.528

10.  Plasminogen activators and their inhibitors in leukemic cell homogenates.

Authors:  H Wada; Y Kumeda; Z Ogasawara; M Ohiwa; T Kaneko; S Tamaki; T Ohno; S Kageyama; T Kobayashi; K Deguchi
Journal:  Am J Hematol       Date:  1993-02       Impact factor: 10.047

View more
  5 in total

1.  Use of tranexamic acid for disseminated intravascular coagulation with excessive fibrinolysis associated with aortic dissection in a patient with chronic renal failure.

Authors:  Shun-Ichi Kimura; Jun Odawara; Takatoshi Aoki; Masayuki Yamakura; Masami Takeuchi; Yoshihiko Watanabe; Kosei Matsue
Journal:  Int J Hematol       Date:  2009-04-21       Impact factor: 2.490

Review 2.  Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia.

Authors:  Arturo J Martí-Carvajal; Vidhu Anand; Ivan Solà
Journal:  Cochrane Database Syst Rev       Date:  2015-06-24

Review 3.  Classifying types of disseminated intravascular coagulation: clinical and animal models.

Authors:  Hidesaku Asakura
Journal:  J Intensive Care       Date:  2014-03-06

Review 4.  Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis.

Authors:  Hidesaku Asakura; Hoyu Takahashi; Toshimasa Uchiyama; Yutaka Eguchi; Kohji Okamoto; Kazuo Kawasugi; Seiji Madoiwa; Hideo Wada
Journal:  Thromb J       Date:  2016-09-28

Review 5.  Recent advances in the research and management of sepsis-associated DIC.

Authors:  Toshiaki Iba; Jean Marie Connors; Isao Nagaoka; Jerrold H Levy
Journal:  Int J Hematol       Date:  2021-01-02       Impact factor: 2.490

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.